| アブストラクト | Objectives To describe the tyrosine kinase inhibitor (TKI) treatment patterns in patients with BCR::ABL-positive chronic myeloid leukemia (CML) in Japan. The secondary objective was to describe healthcare resource utilization and any adverse events of interest. Methods This retrospective observational study was conducted using the Medical Data Vision insurance claims database in Japan. All patients in the database who received at least one prescription of any TKI for the treatment of CML between 2011 and 2019 were included. Patients were followed up for at least 12 months (or until death or loss from the database). All healthcare resource consumption during the follow-up period was recorded. Treatment persistence with TKIs was determined using the Kaplan-Meier survival analysis. Adverse events of interest that occurred during treatment were documented. Results Overall, the most frequently used TKI was dasatinib (411 patients, 54.5%). The median duration of persistence on first-line TKI was 30.6 months; 174 (23.1%) patients moved to a second-line treatment, 46 (6.1%) to a third-line treatment, and 14 (0.2%) to a fourth-line treatment. The most common adverse events were vascular diseases (>/=64% of patients, depending on the TKI). The median annual per capita cost of CML management was yen2,105,000, with the acquisition of TKIs being the main cost driver (median: yen2,026,000 per patient annually). Overall, treatment persistence with TKIs, especially in the later treatment lines, remains relatively short, and patients still experience adverse events during treatment. Conclusion Our results suggest that there is still room for improvement in CML treatment, particularly with regard to new, effective drugs that are better tolerated. |
|---|
| ジャーナル名 | Internal medicine (Tokyo, Japan) |
|---|
| Pubmed追加日 | 2026/6/18 |
|---|
| 投稿者 | Matsuki, Eri; Leboucher, Claire; Touzenil, Salsabil; Quelen, Celine; Chung, Jihye |
|---|
| 組織名 | Division of Hematology, Department of Medicine, Keio University School of;Medicine, Japan.;RWE & Biostatistics, Putnam, France.;RWE & Biostatistics, Putnam, Tunisia.;RWE & Biostatistics, Putnam, UK.;Medical Affairs Division, Novartis Pharma K.K, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42309679/ |
|---|
